global Alunbrig Market Set to Hit USD 370 Million by 2034 at 7.3% CAGR

According to a new report from Intel Market Research, the global Alunbrig market was valued at USD 229 million in 2024 and is projected to reach USD 370 million by 2034, growing at a CAGR of 7.3% during the forecast period. This growth is driven by the increasing prevalence of ALK-positive NSCLC, advancements in targeted cancer therapies, and expanding access to biomarker testing in both developed and emerging markets.

What is Alunbrig?

Alunbrig (brigatinib) is a second-generation oral tyrosine kinase inhibitor (TKI) specifically targeting anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer. As a precision oncology drug, it’s designed for patients who have progressed on or can’t tolerate crizotinib therapy. Unlike traditional chemotherapy, Alunbrig selectively inhibits cancer-driving mutations while demonstrating improved CNS penetration – a crucial factor given NSCLC’s tendency to metastasize to the brain.

This comprehensive market report delivers an in-depth analysis of the Alunbrig landscape, covering everything from molecular mechanisms to commercial adoption patterns. We examine clinical trial outcomes, reimbursement policies across key markets, emerging competitive threats, and strategic manufacturer responses to market shifts.

The competitive intelligence within helps stakeholders benchmark performance against industry leaders, while the treatment algorithm analysis reveals untapped prescribing opportunities. For pharmaceutical executives, investors, and healthcare strategists, this report provides the actionable intelligence needed to navigate this dynamic oncology segment.

📥 Download Sample Report: Alunbrig Market – View in Detailed Research Report

Key Market Drivers

Rising ALK+ NSCLC Incidence and Improved Molecular Diagnostics
With approximately 3-5% of NSCLC patients presenting ALK rearrangements, diagnostic advancements are uncovering more eligible candidates for Alunbrig therapy. The adoption of next-generation sequencing in oncology has increased detection rates by over 40% since 2019, creating a growing addressable patient population. Recent clinical guidelines now mandate biomarker testing at diagnosis, ensuring earlier identification of ALK-positive cases that may benefit from targeted therapies like Alunbrig.
Demonstrated Superiority in Second-Line Treatment
Alunbrig’s 72% overall response rate in treatment-naïve patients and 53% intracranial response rate establish its clinical advantage in managing both systemic disease and brain metastases. The ALTA-1L trial results showed a median progression-free survival of 24 months in first-line use – a significant improvement over earlier ALK inhibitors. These compelling efficacy data continue to drive formulary inclusions and treatment guideline recommendations worldwide.

➤ Real-world evidence studies confirm Alunbrig maintains its efficacy outside clinical trials, with patients experiencing 6-9 additional quality-adjusted life years compared to chemotherapy regimens.

Market Challenges

Intensifying Competitive Pressure – The emergence of next-generation ALK inhibitors like lorlatinib creates pricing pressures, while biosimilar development programs threaten future market share. Competitors increasingly bundle diagnostic testing with therapy initiation, raising the competitive bar.
Toxicity Management Hurdles – Pulmonary events and other adverse effects lead to discontinuation rates of 15-20%, necessitating close monitoring and sometimes switching patients to alternative therapies.
Reimbursement Barriers in Cost-Sensitive Markets – With annual treatment costs exceeding $150,000, payers enforce strict prior authorization requirements. Some healthcare systems limit access to only the sickest patients or require progression on multiple therapies first.

Emerging Opportunities

The accelerating adoption of value-based healthcare models presents novel commercialization pathways for Alunbrig. Strategic opportunities include:

Outcome-based contracting with payers to mitigate cost concerns while demonstrating real-world value
Diagnostic partnerships to improve ALK testing rates in community oncology settings
Expanded access programs in emerging markets through creative pricing strategies
Combination therapy research to extend progression-free survival benefits

These forward-looking strategies could help overcome current market barriers while positioning Alunbrig for sustained growth in an increasingly competitive landscape.

📥 Download Sample PDF: Alunbrig Market – View in Detailed Research Report

Regional Market Insights

North America: Commands the largest market share due to favorable reimbursement, high biomarker testing rates, and rapid adoption of new oncology therapies. The U.S. accounts for over 60% of global Alunbrig revenue.
Europe: Shows varied adoption patterns, with Germany and the UK leading due to robust healthcare infrastructure, while Southern/Eastern Europe lags in access.
Asia-Pacific: Japan and Australia represent mature markets, while China and India offer high-growth potential as diagnostic capabilities improve and middle-class populations expand.
Latin America: Brazil and Mexico drive regional growth through specialized cancer centers, though economic volatility creates reimbursement challenges.

Market Segmentation

By Dosage Strength

30mg tablets
50mg tablets
180mg tablets

By Treatment Line

First-line therapy (in clinical trials)
Second-line therapy
Third-line and beyond

By Distribution Channel

Hospital pharmacies
Specialty pharmacies
Retail pharmacies

By End User

Academic medical centers
Community oncology practices
Government healthcare facilities

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East & Africa

📘 Get Full Report Here: Alunbrig Market – View Detailed Research Report

Competitive Landscape

Takeda Pharmaceutical dominates the current ALK inhibitor market with Alunbrig, leveraging its global commercial infrastructure and deep oncology expertise. However, the competitive environment is evolving rapidly:

Novartis and Roche are developing next-generation ALK inhibitors with improved CNS penetration
Pfizer maintains a strong position with its first-generation ALK inhibitor crizotinib
Emerging biotechs are exploring novel mechanisms to overcome treatment resistance
Generic manufacturers have begun developing biosimilar versions in key markets

Success in this dynamic market will require continuous innovation in clinical development, creative market access strategies, and investment in physician education about Alunbrig’s differentiated profile.

Report Deliverables

Comprehensive 10-year market forecasts through 2034
Deep dives into pipeline developments and clinical trial results
Competitive intelligence on 14+ key industry players
Pricing and reimbursement analysis across major markets
Emerging technology and regulatory impact assessments
Strategic recommendations for manufacturers and investors

📘 Get Full Report Here: Alunbrig Market – View Detailed Research Report

📥 Download Sample Report: Alunbrig Market – View in Detailed Research Report

About Intel Market Research

Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include: